{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:39:33Z","timestamp":1780594773771,"version":"3.54.1"},"reference-count":46,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different definitions. A pooled analysis on chronic migraineurs treated with onabotulinumtoxinA and followed-up for, at least, 9 months was performed. Excellent responders were defined either as patients with a \u226575% decrease in monthly headache days (percent-based excellent responders) or as patients with &lt;4 monthly headache days (frequency-based excellent responders). The characteristics of excellent responders at the baseline were compared with the ones of patients with a &lt;30% decrease in monthly headache days. Percent-based excellent responders represented about 10% of the sample, whilst frequency-based excellent responders were about 5% of the sample. Compared with non-responders, percent-based excellent responders had a higher prevalence of medication overuse and a higher excellent response rate even after the 1st and the 2nd injection. Females were less like to be frequency-based excellent responders. Chronic migraine sufferers without medication overuse and of female sex may find fewer benefits with onabotulinumtoxinA. Additionally, the excellent response status is identifiable after the first cycle.<\/jats:p>","DOI":"10.3390\/ijerph191710975","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:17:23Z","timestamp":1662441443000},"page":"10975","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4031","authenticated-orcid":false,"given":"Raffaele","family":"Ornello","sequence":"first","affiliation":[{"name":"Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, Via Vetoio 1 Coppito, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-1888","authenticated-orcid":false,"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[{"name":"Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayyaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Hull University Teaching Hospitals, Hull HU3 2JZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Negro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant\u2019Andrea Hospital, Sapienza University, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Miscio","sequence":"additional","affiliation":[{"name":"Headache Center, Unit of Neurology, Fondazione IRCCS \u201cCasa Sollievo Della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Santoro","sequence":"additional","affiliation":[{"name":"Headache Center, Unit of Neurology, Fondazione IRCCS \u201cCasa Sollievo Della Sofferenza\u201d, 71013 San Giovanni Rotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[{"name":"Headache Unit, Department of Neurology, Vall D\u2019Hebron University, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D\u2019Hebron Institute of Research (VHIR), Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Silvestro","sequence":"additional","affiliation":[{"name":"Headache Center, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[{"name":"IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Brunelli","sequence":"additional","affiliation":[{"name":"Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9594-9336","authenticated-orcid":false,"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[{"name":"Headache and Neurosonology Unit, Campus Bio-Medico University Hospital, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Grazzi","sequence":"additional","affiliation":[{"name":"Headache Center, Neuroalgology Department, IRCCS Foundation \u201cCarlo Besta\u201d Neurological Institute, Via Celoria, 11, 20133 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9273-2839","authenticated-orcid":false,"given":"Luca","family":"Pani","sequence":"additional","affiliation":[{"name":"Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, 41125 Modena, Italy"},{"name":"Pharmacology Unit, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy"},{"name":"Department of Psychiatry and Behavioral Sciences, University of Miami, Coral Gables, FL 33146, USA"},{"name":"VeraSci, Durham, NC 27707, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-6626","authenticated-orcid":false,"given":"Anna","family":"Andreou","sequence":"additional","affiliation":[{"name":"Headache Service, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[{"name":"Headache Service, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London SE1 7EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Frattale","sequence":"additional","affiliation":[{"name":"Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kamm","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ludwig Maximilians University M\u00fcnchen, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ludwig Maximilians University M\u00fcnchen, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[{"name":"Headache Center, Neurology Unit, Neuromotor and Rehabilitation Department, Azienda USL-IRCCS Di Reggio Emilia, 42122 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Torelli","sequence":"additional","affiliation":[{"name":"Headache Center, University of Parma, 43121 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Filatova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institute for Postgraduate Education, Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Latysheva","sequence":"additional","affiliation":[{"name":"Department of Neurology, Institute for Postgraduate Education, Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gryglas-Dworak","sequence":"additional","affiliation":[{"name":"Headache Center Wroclaw, 50-307 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9811-3526","authenticated-orcid":false,"given":"Marcin","family":"Straburzy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Infectious Diseases, University of Warmia and Mazury, 10-719 Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogera","family":"Butera","sequence":"additional","affiliation":[{"name":"Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Colombo","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[{"name":"Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy"},{"name":"Neurology Unit, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy"},{"name":"Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, 71013 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Department of Neurology, Vall D\u2019Hebron University, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D\u2019Hebron Institute of Research (VHIR), Department of Medicine, Universitat Autonoma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant\u2019Andrea Hospital, Sapienza University, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Guerzoni","sequence":"additional","affiliation":[{"name":"Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, Department of Specialist Medicines, AOU Policlinico di Modena, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0651-1939","authenticated-orcid":false,"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[{"name":"Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L\u2019Aquila, Via Vetoio 1 Coppito, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"Storvner","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: Epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0333102411398400","article-title":"Quality of life impairment, disability and economic burden associated with chronic daily headache focusing on chronic migraine with or without medication overuse: A systematic review","volume":"31","author":"Duru","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40122-021-00253-0","article-title":"Early management of OnabotulinumtoxinA treatment in chronic migraine: Insights from a real-life European multicentre study","volume":"10","author":"Ornello","year":"2021","journal-title":"Pain Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: A review in the prevention of chronic migraine","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/head.13617","article-title":"Onabotulinumtoxin-A in chronic migraine: Should timing and definition of non-responder status be revised?","volume":"59","author":"Vernieri","year":"2019","journal-title":"Headache"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-018-0923-6","article-title":"Early onset of efficacy with erenumab in patients with episodic and chronic migraine","volume":"19","author":"Shwedt","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s10194-021-01230-w","article-title":"Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures","volume":"22","author":"Schwedt","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s10194-022-01393-0","article-title":"Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: Subanalysis of two phase 2b\/3 trials in Japanese and Korean patients","volume":"23","author":"Takeshima","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/head.13654","article-title":"Early onset of efficacy with Fremanezumab for the preventive treatment of chronic migraine","volume":"59","author":"Winner","year":"2021","journal-title":"Headache"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: A comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jnnp-2018-320242","article-title":"Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: A post-hoc analysis","volume":"90","author":"Goadsby","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12372","article-title":"CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine","volume":"54","author":"Ramon","year":"2014","journal-title":"Headache"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2016.01.054","article-title":"Factors associated with favourable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study","volume":"363","author":"Lee","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.13211","article-title":"CGRP and PTX3 as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine: An observational study","volume":"58","author":"Dominguez","year":"2018","journal-title":"Headache"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: Predictors of response. A prospective multicentre descriptive study","volume":"25","author":"Santos","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_21","first-page":"e48","article-title":"Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A","volume":"25","author":"Leira","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fneur.2019.00678","article-title":"Response predictors in chronic migraine: Medication overuse and depressive symptoms negatively impact Onabotulinumtoxin-A treatment","volume":"10","author":"Caratozzolo","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s10194-019-0989-9","article-title":"CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA","volume":"20","author":"Ruiz","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/head.13765","article-title":"Short and mid-term predictors of response to onabotulinumtoxinA: Real-life experience observational study","volume":"60","author":"Alpuente","year":"2020","journal-title":"Headache"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-P\u00edas, E., Guerrero, \u00c1.L., Sierra, \u00c1., Trigo, J., and Garc\u00eda-Azor\u00edn, D. (2021). Daily headache in chronic migraine is a predictive factor of response in patients who had completed three sessions of OnabotulinumtoxinA. Toxins, 13.","DOI":"10.3390\/toxins13060432"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","article-title":"Comparing the relative and absolute effect of erenumab: Is a 50% response enough? Results from the ESTEEMen study","volume":"23","author":"Ornello","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40122-021-00328-y","article-title":"Is there a gender difference in the response to onabotulinumtoxinA in chronic migraine? Insights from a real-life European multicenter study on 2879 patients","volume":"10","author":"Ornello","year":"2021","journal-title":"Pain Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the doule-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the Erueopan Headache Federation","volume":"19","author":"Bendsten","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14737175.2020.1825077","article-title":"What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group","volume":"20","author":"Sacco","year":"2020","journal-title":"Expert. Rev. Neurother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1007\/s10072-022-06195-5","article-title":"The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: A reliable option for the treatment of chronic migraine","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/14737175.2020.1821655","article-title":"Combination therapy in migraine: Asset or issue?","volume":"10","author":"Marteletti","year":"2020","journal-title":"Exp. Rev. Neurother."},{"key":"ref_35","first-page":"623","article-title":"Deprescribing in migraine","volume":"6","author":"Martelletti","year":"2020","journal-title":"Exp. Opin. Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s10194-021-01252-4","article-title":"Burden and attitude to resistant and refractory migraine: A survey from the European Headache Federation with the endorsement of the European Migraine and Headache Alliance","volume":"22","author":"Sacco","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/head.13630","article-title":"Prognosis following discontinuation of OnabotulinumA therapy in \u201csuper-responding\u201d chronic migraine patients","volume":"59","author":"Ching","year":"2019","journal-title":"Headache"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/brain\/awq159","article-title":"Triptan-induced enhacement of neuronal nitric oxide synthetase in trieminal ganglion dural afferents uinderlies increased responsiveness to potential migraine triggers","volume":"133","author":"Ossipov","year":"2010","journal-title":"Brain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1097\/j.pain.0000000000001291","article-title":"Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns","volume":"159","author":"Buonvicino","year":"2018","journal-title":"Pain"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/03331024211017250","article-title":"CGRP release in an experimental human trigeminal pain model","volume":"412","author":"Frese","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-020-01189-0","article-title":"Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: Towards the identification of a panel of peripheral biomarkers of migraine?","volume":"21","author":"Greco","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumotxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Ramon","year":"2015","journal-title":"Pain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of OnabotulinumtoxinA in chronic migraine: A narrative review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/0333102418825382","article-title":"Early onset of effect of onabtoulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","article-title":"A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: A real-world experience","volume":"17","author":"Negro","year":"2015","journal-title":"J. Headache Pain"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13696998.2019.1675417","article-title":"Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK","volume":"23","author":"Curry","year":"2020","journal-title":"J. Med. Econ."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/17\/10975\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:31Z","timestamp":1760142151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/19\/17\/10975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":46,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijerph191710975"],"URL":"https:\/\/doi.org\/10.3390\/ijerph191710975","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}